APPLIED GENETIC TECHNOLOGIES (AGTC) Stock Price, Forecast & Analysis
NASDAQ:AGTC • US03820J1007
AGTC Key Statistics, Chart & Performance
The current stock price of AGTC is 0.3936 USD. In the past month the price decreased by -4.23%. In the past year, price decreased by -79.71%.
AGTC Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to AGTC. When comparing the yearly performance of all stocks, AGTC is a bad performer in the overall market: 83.06% of all stocks are doing better.
AGTC Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AGTC. AGTC has a bad profitability rating. Also its financial health evaluation is rather negative.
AGTC Financial Highlights
Over the last trailing twelve months AGTC reported a non-GAAP Earnings per Share(EPS) of -1.42. The EPS increased by 15.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -122.5% | ||
| ROE | N/A | ||
| Debt/Equity | 0.39 |
AGTC Forecast & Estimates
10 analysts have analysed AGTC and the average price target is 0.37 USD. This implies a price decrease of -6.71% is expected in the next year compared to the current price of 0.3936.
AGTC Ownership
AGTC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.48 | 396.512B | ||
| AMGN | AMGEN INC | 16.63 | 202.199B | ||
| GILD | GILEAD SCIENCES INC | 16.97 | 187.492B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.39 | 119.063B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.78 | 82.713B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.19 | 44.834B | ||
| INSM | INSMED INC | N/A | 34.336B | ||
| NTRA | NATERA INC | N/A | 30.104B | ||
| BIIB | BIOGEN INC | 12.62 | 28.19B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.691B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AGTC
Company Profile
Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the usage of a gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. The company is headquartered in Alachua, Florida and currently employs 102 full-time employees. The company went IPO on 2014-03-27. The firm uses gene therapy platform to develop genetic therapies for patients suffering from rare and debilitating diseases. Its focus is on the field of ophthalmology where it has active clinical programs in X-linked retinitis pigmentosa (XLRP), achromatopsia (ACHM) and a optogenetics program, as well as a preclinical program in dry age-related macular degeneration (dAMD). The company has approximately one preclinical program in otology and two preclinical programs targeting central nervous system disorders (CN), including frontotemporal dementia and amyotrophic lateral sclerosis. Its optogenetics program is being developed in collaboration with Bionic Sight, LLC and its otology program is being developed in collaboration with Otonomy, Inc. In addition to its product pipeline, the Company has also developed broad technological and manufacturing capabilities in synthetic promoter development and optimization.
Company Info
APPLIED GENETIC TECHNOLOGIES
Suite D, 11801 Research Drive
Alachua FLORIDA 32615 US
CEO: Susan B. Washer
Employees: 102
Phone: 13864622204.0
APPLIED GENETIC TECHNOLOGIES / AGTC FAQ
What does AGTC do?
Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the usage of a gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. The company is headquartered in Alachua, Florida and currently employs 102 full-time employees. The company went IPO on 2014-03-27. The firm uses gene therapy platform to develop genetic therapies for patients suffering from rare and debilitating diseases. Its focus is on the field of ophthalmology where it has active clinical programs in X-linked retinitis pigmentosa (XLRP), achromatopsia (ACHM) and a optogenetics program, as well as a preclinical program in dry age-related macular degeneration (dAMD). The company has approximately one preclinical program in otology and two preclinical programs targeting central nervous system disorders (CN), including frontotemporal dementia and amyotrophic lateral sclerosis. Its optogenetics program is being developed in collaboration with Bionic Sight, LLC and its otology program is being developed in collaboration with Otonomy, Inc. In addition to its product pipeline, the Company has also developed broad technological and manufacturing capabilities in synthetic promoter development and optimization.
Can you provide the latest stock price for APPLIED GENETIC TECHNOLOGIES?
The current stock price of AGTC is 0.3936 USD. The price increased by 1.23% in the last trading session.
What is the dividend status of APPLIED GENETIC TECHNOLOGIES?
AGTC does not pay a dividend.
What is the ChartMill technical and fundamental rating of AGTC stock?
AGTC has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is APPLIED GENETIC TECHNOLOGIES (AGTC) stock traded?
AGTC stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of APPLIED GENETIC TECHNOLOGIES (AGTC)?
APPLIED GENETIC TECHNOLOGIES (AGTC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.42).
Can you provide the number of employees for APPLIED GENETIC TECHNOLOGIES?
APPLIED GENETIC TECHNOLOGIES (AGTC) currently has 102 employees.